Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(6 years ago) | |
USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(12 days ago) | |
US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(5 months from now) | |
US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 7 months from now) | |
US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 7 months from now) | |
US7919625 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(2 years from now) | |
US7417148 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(2 years from now) | |
US7767678 (Pediatric) | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
May, 2027
(3 years from now) | |
US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(9 years from now) | |
US11103497 (Pediatric) | PF PRISM CV | Treatment of imatinib resistant leukemia |
Aug, 2034
(10 years from now) |
Bosulif is owned by Pf Prism Cv.
Bosulif contains Bosutinib Monohydrate.
Bosulif has a total of 11 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bosulif are:
Bosulif was authorised for market use on 04 September, 2012.
Bosulif is available in capsule;oral, tablet;oral dosage forms.
Bosulif can be used as a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l, a method of treating a neoplasm, a method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy.
Drug patent challenges can be filed against Bosulif from 26 March, 2026.
The generics of Bosulif are possible to be released after 28 August, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
New Indication(I-923) | Sep 26, 2026 |
Pediatric Exclusivity(PED) | Mar 26, 2027 |
New Indication(I-759) | Dec 19, 2020 |
Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy; A method for treating a bcrabl positive leukemia in a subject that is resistant ...
Dosage: TABLET;ORAL; CAPSULE;ORAL